ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

FDA seeks support for reorganization of cancer programs, but debate continues.

July 9, 2004

Flat Centers Budget Irks House Subcommittee; Porter Repeats Call For Funding Bypass Budget

March 23, 1990

Report Urges NCI To Continue 5 A Day, Expand Funding For Communications.

February 9, 2001

FDA Grants Accelerated Approval to Imbruvica

November 29, 2013

St. Jude, Washington University Plan $65 Million Pediatric Cancer Genome Project

January 29, 2010

Study Tracks Lifestyle Factors For Cancer Burden In Blacks

October 26, 2001